Theralase Technologies (TSE:TLT) has released an update.
Theralase Technologies Inc. has announced a breakthrough where its lead drug, Rutherrin, can be activated by the common diabetes drug Metformin, potentially allowing for precise cancer targeting throughout the body without the need for light or radiation. This discovery is significant as both drugs can cross the blood-brain and tumor-specific barriers, offering a new method for attacking cancer cells, including in the brain. Preclinical tests show that Metformin increases the cancer-fighting reactive oxygen species production when combined with Rutherrin.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
